[Helicobacter pylori eradication for gastric MALT lymphoma].

Shotaro Nakamura, Takayuki Matsumoto, Takanari Kitazono

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Clinical features and efficacy of Helicobacter pylori (H. pylori) eradication for patients with gastric MALT lymphoma are reviewed. Gastric MALT lymphoma comprises 1-5% of all gastric malignancies, while 40-50% of primary gastric lymphomas. In approximately 90% of cases, H. pylori infection plays the causative role in the pathogenesis, and H. pylori eradication is nowadays the first-line treatment for this disease, which leads to complete disease remission in 60-90% of cases. Predictive factors for resistance to eradication therapy include absence of H. pylori infection, deep invasion in the gastric wall, t(11:18)/API2-MALT1, and etc. Recently a large-scale Japanese multicenter study demonstrated that the long-term clinical outcome of gastric MALT lymphoma after H. pylori eradication is excellent.

Original languageEnglish
Pages (from-to)1424-1428
Number of pages5
JournalUnknown Journal
Volume71
Issue number8
Publication statusPublished - Jan 1 2013

Fingerprint

Marginal Zone B-Cell Lymphoma
Helicobacter pylori
Helicobacter Infections
Stomach
R Factors
Multicenter Studies
Familial primary gastric lymphoma
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

[Helicobacter pylori eradication for gastric MALT lymphoma]. / Nakamura, Shotaro; Matsumoto, Takayuki; Kitazono, Takanari.

In: Unknown Journal, Vol. 71, No. 8, 01.01.2013, p. 1424-1428.

Research output: Contribution to journalReview article

Nakamura, S, Matsumoto, T & Kitazono, T 2013, '[Helicobacter pylori eradication for gastric MALT lymphoma].', Unknown Journal, vol. 71, no. 8, pp. 1424-1428.
Nakamura, Shotaro ; Matsumoto, Takayuki ; Kitazono, Takanari. / [Helicobacter pylori eradication for gastric MALT lymphoma]. In: Unknown Journal. 2013 ; Vol. 71, No. 8. pp. 1424-1428.
@article{c56a55442a1e412d9d3474fc4d9f69b0,
title = "[Helicobacter pylori eradication for gastric MALT lymphoma].",
abstract = "Clinical features and efficacy of Helicobacter pylori (H. pylori) eradication for patients with gastric MALT lymphoma are reviewed. Gastric MALT lymphoma comprises 1-5{\%} of all gastric malignancies, while 40-50{\%} of primary gastric lymphomas. In approximately 90{\%} of cases, H. pylori infection plays the causative role in the pathogenesis, and H. pylori eradication is nowadays the first-line treatment for this disease, which leads to complete disease remission in 60-90{\%} of cases. Predictive factors for resistance to eradication therapy include absence of H. pylori infection, deep invasion in the gastric wall, t(11:18)/API2-MALT1, and etc. Recently a large-scale Japanese multicenter study demonstrated that the long-term clinical outcome of gastric MALT lymphoma after H. pylori eradication is excellent.",
author = "Shotaro Nakamura and Takayuki Matsumoto and Takanari Kitazono",
year = "2013",
month = "1",
day = "1",
language = "English",
volume = "71",
pages = "1424--1428",
journal = "Quaternary International",
issn = "1040-6182",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - [Helicobacter pylori eradication for gastric MALT lymphoma].

AU - Nakamura, Shotaro

AU - Matsumoto, Takayuki

AU - Kitazono, Takanari

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Clinical features and efficacy of Helicobacter pylori (H. pylori) eradication for patients with gastric MALT lymphoma are reviewed. Gastric MALT lymphoma comprises 1-5% of all gastric malignancies, while 40-50% of primary gastric lymphomas. In approximately 90% of cases, H. pylori infection plays the causative role in the pathogenesis, and H. pylori eradication is nowadays the first-line treatment for this disease, which leads to complete disease remission in 60-90% of cases. Predictive factors for resistance to eradication therapy include absence of H. pylori infection, deep invasion in the gastric wall, t(11:18)/API2-MALT1, and etc. Recently a large-scale Japanese multicenter study demonstrated that the long-term clinical outcome of gastric MALT lymphoma after H. pylori eradication is excellent.

AB - Clinical features and efficacy of Helicobacter pylori (H. pylori) eradication for patients with gastric MALT lymphoma are reviewed. Gastric MALT lymphoma comprises 1-5% of all gastric malignancies, while 40-50% of primary gastric lymphomas. In approximately 90% of cases, H. pylori infection plays the causative role in the pathogenesis, and H. pylori eradication is nowadays the first-line treatment for this disease, which leads to complete disease remission in 60-90% of cases. Predictive factors for resistance to eradication therapy include absence of H. pylori infection, deep invasion in the gastric wall, t(11:18)/API2-MALT1, and etc. Recently a large-scale Japanese multicenter study demonstrated that the long-term clinical outcome of gastric MALT lymphoma after H. pylori eradication is excellent.

UR - http://www.scopus.com/inward/record.url?scp=84886563284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886563284&partnerID=8YFLogxK

M3 - Review article

C2 - 23967674

AN - SCOPUS:84886563284

VL - 71

SP - 1424

EP - 1428

JO - Quaternary International

JF - Quaternary International

SN - 1040-6182

IS - 8

ER -